(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
05 January 2023 (05.01.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/278619 A1

(51) International Patent Classification:
G16B 30/00 (2019.01)

(21) International Application Number:
PCT/US2022/035585

(22) International Filing Date:
29 June 2022 (29.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/217,933 02 July 2021 (02.07.2021) US

(71) Applicant: **KITE PHARMA, INC.** [US/US]; 2400 Broadway, Santa Monica, California 90404 (US).

(72) Inventors: **ANDRADE, Jorge**; c/o Kite Pharma, Inc., 2400 Broadway, Santa Monica, California 90404 (US). **BOLOTIN, Eugene**; c/o Kite Pharma, Inc., 2400 Broadway, Santa Monica, California 90404 (US). **FALK, Alexander S.**; c/o Kite Pharma, Inc., 2400 Broadway, Santa Monica, California 90404 (US). **LIAO, Edward H.**; c/o Kite Pharma, Inc., 2400 Broadway, Santa Monica, California 90404 (US).

(74) Agent: **LOPEZ, Miguel A.** et al.; c/o Kite Pharma, Inc., 2400 Broadway, Santa Monica, California 90404 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH,

(54) Title: A METHOD FOR IDENTIFYING VARIANTS IN GENE PRODUCTS FROM GENE CONSTRUCTS USED IN CELL THERAPY APPLICATIONS



FIG. 2

(57) Abstract: A method for ensuring that gene products used in cell therapy do not carry a risk of reduced efficacy or toxicity due to production of unintended variants. The method includes performing an in-silico analysis on the gene construct to identify and alter sequences likely to cause variants. Also, the method includes performing an in-vivo analysis consisting of RNA-sequence of construct based products. Variant detection may then be performed based on gapped reads from the RNA-sequence to determine variant expression levels, variant significance. The method may include repeating the in-silico analysis if identified variants are unacceptable.

WO 2023/278619 A1

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*